Navigation Links
H3 Biomedicine and Selvita Announce Strategic Collaboration to Develop Precision Cancer Medicines
Date:9/16/2013

CAMBRIDGE, Mass. and KRAKOW, Poland, Sept. 16, 2013 /PRNewswire/ -- H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), one of the largest drug discovery companies in Eastern Europe, announced today that they have entered into a strategic collaboration to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and druggability of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets. 

(Logo: http://photos.prnewswire.com/prnh/20120430/NY96379LOGO )

Recent advances in human cancer genomics have revealed novel target opportunities that will enable new approaches to developing cancer medicines. H3 Biomedicine has built extensive and proprietary target acumen. It has also implemented a set of unique tools and research engines in the areas of cancer genomics, bioinformatics and target validation to lend biological insight to genomic findings. These capabilities will help to accelerate its collaborative drug discovery and development efforts. Selvita started its first kinase discovery programs in 2008 and, over the last five years, has built a premium scientific team with one of the world's most robust kinase discovery platforms. Together, the two companies have the know-how to leverage data from the new target opportunities revealed through cancer genomics.

"Our goal at H3 Biomedicine is to – in a very focused way – utilize the genomic information from public and proprietary data sets to identify and validate highly relevant cancer genes and to develop effective therapies against those targets," stated

SOURCE H3 Biomedicine Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
2. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
3. Cellular Biomedicine Group Announces Appointment of Corporate Controller
4. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5. Cellular Biomedicine Group Provides Update and 2013 Milestones
6. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
10. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
11. A 300 Million Euro Boost for Biomedicine in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... $2.1 million. The orders consist of three large odour control ... . "These orders are consistent with the ... Peter Bruijns , President and CEO. "After a difficult ... we are now beginning to see sales growth. Our lower ...
(Date:9/2/2014)... September 02, 2014 PMG Research, ... 11th clinical research site: PMG Research of Rocky Mount. ... operation of the clinical research department at Boice-Willis ... presence in eastern North Carolina. This new site enhances ... patients in Rocky Mount and the surrounding communities, this ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Spherix Incorporated ... and monetization of intellectual property, today announced that the ... patents to the Company in the month of August ... patents.  The issued patents are: ... , U.S.RE45,081 issued August 19, 2014; and , ...
(Date:9/2/2014)... September 2, 2014 Culot brings ... and lab management services  BioData, producer of ... pleased to announce the appointment of Louis Culot ... served as VP Marketing and Business Development at BioDiscovery ... and clinical applications. Previously, Culot worked for ...
Breaking Biology Technology:PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2Louis Culot Appointed as BioData's CEO 2
... empower transplant patients ... and their ... (Pink Sheets: ALPMF), a leader in the field of transplantation, ... announced a collaborative partnership to jointly,develop further materials for the ...
... new class of anti-infectives, to ... advise Company on pexiganan development, WELLESLEY HILLS, Mass., Oct. ... following its,acquisition of rights to pexiganan, Michael Zasloff, M.D. has ... skin of the African clawed frog while at NIH (National ...
... SUNNYVALE, Calif., Oct. 16 Kyphon Inc.,(Nasdaq: KYPH ... the merger agreement with Medtronic, Inc. (NYSE: MDT ... As previously announced, on July 26, 2007, Kyphon entered ... Medtronic,agreed to acquire all of the outstanding shares of ...
Cached Biology Technology:Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 2MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 3MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 4MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 5Kyphon Stockholders Approve Merger with Medtronic 2
(Date:9/2/2014)... With their long, spiky legs and their propensity for ... stuff of nightmares. And now research from North Carolina ... spread into homes across the eastern United States. , ... or pose any kind of threat to humans," says ... State and lead author of a paper about the ...
(Date:9/2/2014)... of lithographic limestone is well known as a ... that area (for example, Archaeopteryx). Now, for the ... the French equivalent of these outcrops - discoveries ... known water treader. , Despite the abundance of ... have been obtained from the Late Kimmeridgian equivalents ...
(Date:9/2/2014)... a hot oven, you rapidly pull your hand away. ... sensing and responding to such painful stimuli, they are ... have made a surprising discovery about the role of ... have built a structural model of the molecule. These ... may help direct new strategies to treat pain in ...
Breaking Biology News(10 mins):Researchers find Asian camel crickets now common in US homes 2Exceptionally well preserved insect fossils from the Rhône Valley 2Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3
... occurring in the Sundarbans, resulting in as much as 200m ... published today (11th Jan) in Remote Sensing by ... as human development thrives, and global temperature continues to rise, ... at alarming rates. This will inevitably lead to species loss ...
... are "apple-shaped" with fat more concentrated around the abdomen ... such as heart disease and diabetes than those who are ... thighs. But new research conducted at UC Davis ... and Metabolism provides further evidence that the protective benefits ...
... Oxidative stress is a primary villain in a host ... to Alzheimer,s disease, Amyotrophic Lateral Sclerosis and Parkinson,s disease. ... Research Institute (TSRI) have found that blocking the interaction ... neurons associated with these neurodegenerative diseases, suggesting a potential ...
Cached Biology News:Bengali forests are fading away 2UC Davis study deflates notion that pear-shaped bodies more healthy than apples 2UC Davis study deflates notion that pear-shaped bodies more healthy than apples 3Scripps Florida scientists uncover potential drug target to block cell death in Parkinson's disease 2
Form: Ready to use Applications: ELISA...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Defender against cell death 1...
Biology Products: